EUVIMEDEUVIMED entdecken
Crossref

Functional determination of emicizumab in presence of factor VIII activity

Nasim Shahidi Hamedani, Anouk Anna Marie Therese Donners, Matthijs van Luin, Simone Gasper, Heiko Rühl, Claudia Klein, Thilo Albert, Mohsin El Amrani, Bernd Pötzsch, Johannes Oldenburg, Jens Müller

Journal of Thrombosis and Haemostasis · 2023

DOI: 10.1016/j.jtha.2023.09.011 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Thrombosis and Haemostasis, 2023. Verfasst von Nasim Shahidi Hamedani und 10 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Experimental Hematology and Transfusion Medicine, University Hospital Bonn, Bonn, Germany. Hauptthemen laut MEDLINE: Hemophilia A, Antibodies, Bispecific, Hemostatics. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 38 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Accurate measurement of emicizumab in the presence of factor (F) VIII is required in patients with severe hemophilia A treated with emicizumab, as well as additional need for FVIII substitution or emicizumab prophylaxis in patients with acquired or moderate to mild hemophilia A. However, the presence of FVIII potentially biases the results. OBJECTIVES: To assess the impact of plasma FVIII activity on determined emicizumab levels and evaluate different strategies for correction for or preanalytical inhibition of FVIII. METHODS: Evaluated strategies comprised of the following: (1) calculation of actual emicizumab plasma levels based on measured FVIII activities and FVIII-affected emicizumab values, (2) preanalytical heat treatment (56 °C for 40 minutes), and (3) neutralization of FVIII activity using FVIII inhibitors. Emicizumab levels and FVIII activities were measured using a modified FVIII one-stage clotting assay and a chromogenic FVIII assay based on bovine factors, respectively. RESULTS: Spiking experiments revealed a consistent linear association between FVIII activities and determined (FVIII-affected) emicizumab results at different emicizumab input levels (∼0.12 μg/mL per IU/dL of FVIII). This principally allowed for mathematical correction of measured emicizumab levels in the presence of FVIII. While a 40% to 50% activity loss of intrinsic plasma emicizumab through heat treatment was observed in patient samples, emicizumab spiked into FVIII-deficient plasma was not or only marginally affected. Application of inhibitor-based FVIII neutralization led to good agreement of results when compared with direct quantification of emicizumab by liquid chromatography-tandem mass spectrometry. CONCLUSION: Inhibitor-based FVIII neutralization appears to be a feasible strategy for accurate measurement of plasma emicizumab levels in the presence of FVIII activity.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hemophilia AAntibodies, BispecificHemostaticsHumansAnimalsCattleFactor VIIIPartial Thromboplastin TimeAntibodies, Monoclonal, Humanized

Stichwörter der Autor:innen

emicizumabfactor VIIIhemophilia Aneutralizing antibodypreanalytical phase

Substanzen

Factor VIIIAntibodies, BispecificHemostaticsemicizumabAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Institute of Experimental Hematology and Transfusion Medicine, University Hospital Bonn, Bonn, Germany.
  • Department of Clinical Pharmacy, Division Laboratories, Pharmacy and Biomedical Genetics, University Medical Center Utrecht, Utrecht, The Netherlands.
  • Institute of Experimental Hematology and Transfusion Medicine, University Hospital Bonn, Bonn, Germany. Electronic address: jens.mueller@ukbonn.de.

Zitieren

APA

Hamedani, N. S., Donners, A. A. M. T., van Luin, M., Gasper, S., Rühl, H., Klein, C., Albert, T., El Amrani, M., Pötzsch, B., Oldenburg, J., & Müller, J. (2023). Functional determination of emicizumab in presence of factor VIII activity. Journal of Thrombosis and Haemostasis. https://doi.org/10.1016/j.jtha.2023.09.011

Vancouver

Hamedani NS, Donners AAMT, van Luin M, Gasper S, Rühl H, Klein C, et al. Functional determination of emicizumab in presence of factor VIII activity. Journal of Thrombosis and Haemostasis. 2023. doi:10.1016/j.jtha.2023.09.011

BibTeX
@article{Hamedani2023,
  author = {Hamedani, Nasim Shahidi and Donners, Anouk Anna Marie Therese and van Luin, Matthijs and Gasper, Simone and Rühl, Heiko and Klein, Claudia and Albert, Thilo and El Amrani, Mohsin and Pötzsch, Bernd and Oldenburg, Johannes and Müller, Jens},
  title = {Functional determination of emicizumab in presence of factor VIII activity},
  journal = {Journal of Thrombosis and Haemostasis},
  year = {2023},
  doi = {10.1016/j.jtha.2023.09.011}
}
Kostenlos starten →